Division of Oncology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, Korea.
J Korean Med Sci. 2011 Jul;26(7):954-8. doi: 10.3346/jkms.2011.26.7.954. Epub 2011 Jun 20.
A 31-yr-old man with abdominal pain was diagnosed with a pancreatic endocrine tumor and multiple hepatic metastases. Despite optimal treatment with interferon alpha, a somatostatin analog, local therapy with high-intensity focused ultrasound ablation for multiple hepatic metastases, and multiple lines of chemotherapy with etoposide/cisplatin combination chemotherapy and gemcitabine monotherapy, the tumor progressed. As few chemotherapeutic options were available for him, sorafenib (800 mg/day, daily) was administered as a salvage regimen. Sorafenib was continued despite two episodes of grade 3 skin toxicity; it delayed tumor progression compared to the previous immunotherapy and chemotherapy. Serial computed tomography scans showed that the primary and metastatic tumors were stable. Thirteen months after beginning targeted therapy, and up to the time of this report, the patient is well without disease progression. We suggest that sorafenib is effective against pancreatic endocrine tumors.
一位 31 岁男性因腹痛被诊断为胰腺内分泌肿瘤和多发肝转移。尽管接受了最佳治疗，包括干扰素 α、生长抑素类似物、高强度聚焦超声消融治疗多发肝转移、多线化疗（依托泊苷/顺铂联合化疗和吉西他滨单药化疗），肿瘤仍进展。由于他的化疗选择有限，给予索拉非尼（800mg/天，每日）作为挽救治疗方案。尽管出现了两度 3 级皮肤毒性，但仍继续使用索拉非尼；与之前的免疫治疗和化疗相比，它延迟了肿瘤进展。连续的计算机断层扫描显示原发和转移肿瘤稳定。开始靶向治疗 13 个月后，截至本报告时，患者病情良好，无疾病进展。我们建议索拉非尼对胰腺内分泌肿瘤有效。
